ALXO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ALX Oncology Holdings Inc (ALXO) is not a strong buy at this time for a beginner investor with a long-term strategy. While there are some positive catalysts in the pipeline, the company's weak financial performance, insider selling trends, and lack of immediate trading signals suggest it is better to hold off on investing until more favorable conditions arise.
The MACD histogram is negative (-0.0308) and contracting, indicating a bearish trend. RSI is at 33.92, which is neutral but leaning towards oversold territory. Moving averages are converging, showing no clear trend. The stock is trading near its support level of 1.638, with resistance at 1.978.
Recent appointment of Jeff Knight as Chief Development and Operating Officer, bringing over 30 years of experience.
Promising clinical programs (evorpacept and ALX
expected to be significant catalysts within 12-18 months.
Analysts have given positive ratings with price targets ranging from $4 to $6, citing potential blockbuster programs in oncology.
Insiders are selling heavily, with a 2135% increase in selling activity over the last month.
Weak financial performance in Q4 2025, with a net income drop of -21.65% YoY and EPS decline of -22.22%.
No recent congress trading data or influential figure activity to support the stock.
The company reported no revenue growth in Q4 2025, with net income dropping to -$22.85 million (-21.65% YoY) and EPS falling to -0.42 (-22.22% YoY). Gross margin remains at 0%.
Analysts are optimistic about ALXO's long-term potential, with ratings of Overweight and Buy from firms like Wells Fargo, H.C. Wainwright, UBS, and Piper Sandler. Price targets range from $4 to $6, driven by the company's oncology pipeline and potential catalysts in 2026-2027.
